For "whatever" reason management is not telling us exactly what is going on with Europe. I wonder if somehow a potential partner (or acquirer) may be involved in helping AMRN in some way with the filing. Europe will be (potentially) a very lucrative market without competition so for many "potential" partners it may be a must have. Obviously, from the Dow Jones interview with JT it sounds as if Novartis may be very interested, perhaps even to the point of acquiring AMRN. Europe was under consideration for partnering a long time ago but management held off. Europe will require either a distribution agreement or an outright buyout. The lack of the former keeps the latter alive.